A study of Oxaliplatin in combination with LV/5-Fu as first-line treatment for metastatic gastrointestinal cancers
- VernacularTitle:奥沙利铂联合亚叶酸钙和5-氟尿嘧啶一线治疗晚期胃肠道肿瘤的研究
- Author:
Dianshui SUN
- Publication Type:Journal Article
- Keywords:
Gastrointestinal neoplasms?Oxaliplatin?Leucovorin?5-Fluorouracil?Drug therapy
- From:
Chinese Journal of Current Advances in General Surgery
1999;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of Oxaliplatin(OXA)/LV/5-Fu regimen as first-line treatment for patients with metastatic gastrointestinal cancers.Methods: OXA 130mg/m2 d 1,LV 200mg d 1-5 followed by 5-Fu 450mg/m2 d 1-5 ,and repeated every 3 weeks.Efficacy was evaluated after 2 cycles(6 weeks).Results: Fifty-eight patients were entered into the study.All patients were metastatic after a curative resection or metastatic without a curative resection..All patients were evaluated for clinical response and toxicity.2 patients achieved CR(3.4%),26 PR(44.8%),21 SD(36.2%),and 9 PD(15.5%),ORR 48.3%.Overall response rate for patients with gastric cancer or colorectal cancer ,and patients resected or non-resected were 44.4%,51.6%,54.5%,40.0% respectively. The most frequent side-effects were nausea/vomiting, neurotoxicity, leucopenia and thrombocytopenia,and there were no deaths during treatment.Conclusion:OXA/LV/5-Fu is a high response regimen for metastatic gastrointestinal cancers with mild toxicity,which can be practiced safely.
